BRISTOL-MYERS SQUIBB COMPANY Payment for Debt Extinguishment or Debt Prepayment Cost
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $6.60 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-02-12
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-06-30 was $6.60B.
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-03-31 was $5.80B, a 45.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $6.60B, a 65.00% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $4.00B.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $6.60B derived: sum of 3 quarters · filed 2025-02-12 | $6.60B 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $6.60B derived: sum of 2 quarters · filed 2023-10-26 | $6.60B 10-Q · filed 2023-10-26 | $12.40B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $6.60B 10-Q · filed 2022-07-27 | $6.60B 10-Q · filed 2023-07-27 | $12.40B derived: sum of 3 quarters · filed 2024-02-13 | $12.40B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $5.80B 10-Q · filed 2023-04-27 | $5.80B derived: sum of 2 quarters · filed 2024-02-13 | $5.80B derived: sum of 3 quarters · filed 2024-02-13 | $5.80B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $0.00 derived: sum of 2 quarters · filed 2024-02-13 | $0.00 derived: sum of 3 quarters · filed 2024-02-13 | $4.00B 10-K · filed 2024-02-13 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $0.00 derived: sum of 2 quarters · filed 2022-10-26 | $4.00B 10-Q · filed 2022-10-26 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $4.00B 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $4.00B 10-Q · filed 2022-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |